Showing results (691-700 of 2,132) with videos related to
Sort By:
Pageof 214
Biopharmaceutics & Drug Disposition|February 17, 2018
An iminium ion metabolite hampers the production of the pharmacologically active metabolite of a multikinase inhibitor KW-2449 in primates: irreversible inhibition of aldehyde oxidase and covalent binding with endogenous proteinsJun Hosogi, Rui Ohashi, Hiroshi Maeda, et al.Biopharmaceutics & Drug Disposition|January 24, 2023
Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug dispositionSagnik Chatterjee, Anup Arunrao Deshpande, Hong ShenBiopharmaceutics & Drug Disposition|December 18, 2001
Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft modelY Tsukamoto, Y Kato, M Ura, et al.Biopharmaceutics & Drug Disposition|December 18, 2001
Dose-dependent pharmacokinetics of a new reversible proton pump inhibitor, DBM-819, after intravenous and oral administration to rats: hepatic first-pass effectE J Kim, S O Kim, D H Lee, et al.Biopharmaceutics & Drug Disposition|December 26, 2001
Nonstationary disposition of valproic acid during prolonged intravenous infusion: contributions of unbound clearance and protein bindingT L Arens, G M PollackBiopharmaceutics & Drug Disposition|April 17, 2001
Pharmacokinetics and protein binding of the selective neuronal nitric oxide synthase inhibitor 7-nitroindazoleM A Bush, G M PollackBiopharmaceutics & Drug Disposition|April 17, 2001
Comparative bioavailability of two cefadroxil formulations in healthy human volunteers after a single-dose administrationC H Oliveira, J Salmon, M Sucupira, et al.Biopharmaceutics & Drug Disposition|August 14, 2002
Pharmacokinetics and metabolism of the novel synthetic C-nucleoside, 1-(2-deoxy-beta-D-ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridinePanteha Khalili, Ebrahim Naimi, Edward E Knaus, et al.Biopharmaceutics & Drug Disposition|September 6, 2002
The outstanding metabolic stability of a 14C-labeled beta-nonapeptide in rats--in vitro and in vivo pharmacokinetic studiesHansjörg Wiegand, Bernard Wirz, Alain Schweitzer, et al.Biopharmaceutics & Drug Disposition|August 22, 2001
Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specificationsN B Modi, A Lam, E Lindemulder, et al.Pageof 214